Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Active, not recruiting · Phase 2 · NCT06444880
Conditions: SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary Carcinoma
At a glance
- Research payments reported, 2025
- $350,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 15
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with Regeneron Pharmaceuticals)
- Tested
- Ubamatamab (drug), Cemiplimab (drug)
- Dates
- Started 2024-10-09; completion 2028-07-31
- Results posted
- Not yet
To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $350,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $350,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.